Taysha Gene Therapies, Inc. (NASDAQ: TSHA)
$1.7650
-0.1650 ( -5.62% ) 843.8K
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Market Data
Open
$1.7650
Previous close
$1.9300
Volume
843.8K
Market cap
$361.73M
Day range
$1.7250 - $1.8950
52 week range
$1.1900 - $4.3200
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jan 03, 2025 |
4 | Insider transactions | 1 | Jan 03, 2025 |
4 | Insider transactions | 1 | Jan 03, 2025 |
10-q | Quarterly Reports | 97 | Nov 13, 2024 |
8-k | 8K-related | 14 | Nov 13, 2024 |
8-k | 8K-related | 14 | Aug 12, 2024 |
10-q | Quarterly Reports | 98 | Aug 12, 2024 |
4 | Insider transactions | 1 | Jul 01, 2024 |
8-k | 8K-related | 19 | Jun 26, 2024 |
8-k | 8K-related | 29 | Jun 26, 2024 |